viewAllergy Therapeutics PLC

Allergy Therapeutics earnings to exceed expectations after a strong year

Net revenues for the 12 months ended June 30 were £78.2mln, up 6% year-on-year

Allergy Therapeutics PLC -

Allergy Therapeutics PLC (LON:AGY) has said its earnings are likely to exceed expectations after a strong year.

Net revenues for the 12 months ended June 30, 2020, were £78.2mln, up 6%, it said, while the firm was in a strong financial position with £37mln in the bank at the period end.

The performance of the group, which develops and sells short course allergy inoculations, was particularly impressive given the challenges in the closing quarter of the year posed by the coronavirus (COVID-19) lockdown.

Allergy's chief executive Manuel Llobet praised his team’s “robust and rapid response” to the strictures imposed by the outbreak. Part of this response was to create a COVID-19 diagnostic facility, which has now been approved by Spanish authorities.

Allergy said its strong financial position meant it was able to fully fund the upcoming Grass MATA MPL pilot and pivotal phase III field studies and the phase I peanut trial with just ”a small amount of additional debt”.

“Our plans to develop a strong R&D pipeline remain on track and our two recently signed agreements with partners provide exciting new opportunities for our VLP technology and our oral treatment offerings for allergy patients,” CEO Llobet said in the trading update.

Quick facts: Allergy Therapeutics PLC

Price: 13.63 GBX

Market: AIM
Market Cap: £86.86 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...



Market Report: Coronavirus vaccine update sparks FTSE 100 rally

Headlines from the Proactive UK newsroom. The FTSE 100 rallied 60 points to 6,240 on COVID-19 vaccine hopes. US group Moderna’s early stage trial of a coronavirus vaccine proved safe and sparked some immune response. UK inflation picked up to 0.6% led by demand for online computer games...

2 weeks, 6 days ago

2 min read